The Japan's Ministry of Health, Labor and Welfare (MHLW) has granted reimbursement coverage for Cambridge Heart's microvolt t-wave alternans (MTWA) test.

Cambridge said the MTWA Test will be reimbursed for patients who are considered at risk for arrhythmias including patients with a history of heart attack, cardiomyopathy and Brugada syndrome.

Toho University Medical Center medicine professor Takanori Ikeda said a large body of clinical evidence supports the predictive value of the test which can now be used to help identify and manage the risk of arrhythmias.

Cambridge Heart president and CEO Ali Haghighi-Mood said the company markets its MTWA technology in Japan through its partnership with Fukuda Denshi.

"We look forward to working closely and strategically with our distribution partner in Japan to further expand that market and maximize the value of the relationship," Haghighi-Mood added.